Compare Stocks: BOLD, CAMP, MGNX, and AKBA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.98 -0.5%	$1.13	$0.81 ▼ $3.20	$270.18M	0.19	4.47 million shs	3.33 million shs
BOLD Boundless Bio	$2.86 -1.0%	$2.65	$0.96 ▼ $3.16	$65.07M	-0.03	590,945 shs	15,709 shs
CAMP CAMP4 Therapeutics	$4.08 +7.4%	$4.11	$1.44 ▼ $7.75	$256.02M	0.27	191,909 shs	820,482 shs
MGNX MacroGenics	$4.22 -2.3%	$4.21	$1.29 ▼ $5.08	$268.81M	1.22	1.01 million shs	219,625 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+3.77%	+8.14%	-25.17%	+1.06%	-68.48%
BOLD Boundless Bio	0.00%	-0.69%	+12.45%	+96.60%	+151.30%
CAMP CAMP4 Therapeutics	+0.26%	-9.52%	-9.74%	-11.63%	+147.40%
MGNX MacroGenics	+6.93%	+6.93%	+13.09%	+1.65%	+148.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.98 -0.5%	$1.13	$0.81 ▼ $3.20	$270.18M	0.19	4.47 million shs	3.33 million shs
BOLD Boundless Bio	$2.86 -1.0%	$2.65	$0.96 ▼ $3.16	$65.07M	-0.03	590,945 shs	15,709 shs
CAMP CAMP4 Therapeutics	$4.08 +7.4%	$4.11	$1.44 ▼ $7.75	$256.02M	0.27	191,909 shs	820,482 shs
MGNX MacroGenics	$4.22 -2.3%	$4.21	$1.29 ▼ $5.08	$268.81M	1.22	1.01 million shs	219,625 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+3.77%	+8.14%	-25.17%	+1.06%	-68.48%
BOLD Boundless Bio	0.00%	-0.69%	+12.45%	+96.60%	+151.30%
CAMP CAMP4 Therapeutics	+0.26%	-9.52%	-9.74%	-11.63%	+147.40%
MGNX MacroGenics	+6.93%	+6.93%	+13.09%	+1.65%	+148.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	2.33	Hold	$3.75	284.62% Upside
BOLD Boundless Bio	1.00	Sell	N/A	N/A
CAMP CAMP4 Therapeutics	2.67	Moderate Buy	$9.56	134.38% Upside
MGNX MacroGenics	2.17	Hold	$6.33	50.08% Upside

Current Analyst Ratings Breakdown

Latest BOLD, CAMP, MGNX, and AKBA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/31/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	MGNX MacroGenics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$9.00 ➝ $11.00
8/17/2026	CAMP CAMP4 Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/14/2026	CAMP CAMP4 Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	CAMP CAMP4 Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
8/14/2026	CAMP CAMP4 Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$12.00 ➝ $15.00
8/7/2026	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$1.00
8/6/2026	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	MGNX MacroGenics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/3/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$236.20M	1.14	N/A	N/A	$0.09 per share	10.83
BOLD Boundless Bio	N/A	N/A	N/A	N/A	$2.90 per share	N/A
CAMP CAMP4 Therapeutics	$3.50M	73.15	N/A	N/A	($0.01) per share	-408.00
MGNX MacroGenics	$175.14M	1.53	N/A	N/A	$0.67 per share	6.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$5.34M	-$0.11	N/A	N/A	N/A	-13.54%	-88.88%	-7.74%	11/9/2026 (Estimated)
BOLD Boundless Bio	-$58.20M	-$2.86	N/A	N/A	N/A	N/A	-70.89%	-47.37%	N/A
CAMP CAMP4 Therapeutics	-$80.40M	-$2.32	N/A	N/A	N/A	-2,543.74%	-252.79%	-85.65%	N/A
MGNX MacroGenics	-$74.62M	-$0.22	N/A	N/A	N/A	-8.70%	-109.26%	-18.70%	11/11/2026 (Estimated)

Latest BOLD, CAMP, MGNX, and AKBA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CAMP CAMP4 Therapeutics	-$0.24	-$0.58	-$0.34	-$0.58	N/A	$1.78 million
8/13/2026	Q2 2026	MGNX MacroGenics	-$0.0779	$0.31	+$0.3879	$0.31	$59.14 million	$32.83 million
8/7/2026	Q2 2026	BOLD Boundless Bio	N/A	-$1.06	N/A	-$1.06	N/A	N/A
8/5/2026	Q2 2026	AKBA Akebia Therapeutics	-$0.0420	-$0.02	+$0.0220	-$0.03	$48.85 million	$49.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
BOLD Boundless Bio	N/A	N/A	N/A	N/A	N/A
CAMP CAMP4 Therapeutics	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	0.99	1.43	1.35
BOLD Boundless Bio	N/A	9.48	9.48
CAMP CAMP4 Therapeutics	N/A	4.70	4.70
MGNX MacroGenics	N/A	2.96	2.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
BOLD Boundless Bio	N/A
CAMP CAMP4 Therapeutics	N/A
MGNX MacroGenics	96.89%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	4.30%
BOLD Boundless Bio	23.10%
CAMP CAMP4 Therapeutics	21.69%
MGNX MacroGenics	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	277.11 million	265.19 million	Optionable
BOLD Boundless Bio	64	22.75 million	17.49 million	No Data
CAMP CAMP4 Therapeutics	644	62.75 million	49.14 million	No Data
MGNX MacroGenics	430	63.70 million	55.04 million	Optionable

BOLD, CAMP, MGNX, and AKBA Headlines

Recent News About These Companies

BlackRock Inc. Takes $21.62 Million Position in MacroGenics, Inc. $MGNX

September 3 at 3:35 AM | marketbeat.com

MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts

August 28, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Purchases New Position in MacroGenics, Inc. $MGNX

August 28, 2026 | marketbeat.com

Bank of America Corp DE Buys 564,094 Shares of MacroGenics, Inc. $MGNX

August 26, 2026 | marketbeat.com

MacroGenics (NASDAQ:MGNX) VP Sells $129,085.75 in Stock

August 21, 2026 | insidertrades.com

Insider Selling: MacroGenics (NASDAQ:MGNX) VP Sells 31,105 Shares of Stock

August 20, 2026 | marketbeat.com

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

August 20, 2026 | zacks.com

MacroGenics (NASDAQ:MGNX) Posts Earnings Results, Beats Estimates By $0.39 EPS

August 13, 2026 | marketbeat.com

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

August 13, 2026 | zacks.com

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

August 13, 2026 | globenewswire.com

MacroGenics, Inc. $MGNX Shares Bought by Wasatch Advisors LP

August 13, 2026 | marketbeat.com

MacroGenics, Inc.: MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

August 12, 2026 | finanznachrichten.de

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

August 11, 2026 | globenewswire.com

MacroGenics (MGNX) Projected to Release Earnings on Thursday

August 6, 2026 | marketbeat.com

MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important

July 27, 2026 | seekingalpha.com

MacroGenics Advances MGC026 in Phase 1 Oncology Trial

July 25, 2026 | theglobeandmail.com

MacroGenics slips after early-stage trial data for lead asset

July 24, 2026 | seekingalpha.com

MacroGenics, Inc.: MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

July 24, 2026 | finanznachrichten.de

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

July 23, 2026 | tmcnet.com

MacroGenics announces upcoming board change with director resignation

July 8, 2026 | tipranks.com

Bora Pharmaceuticals closes 122 million buy of MacroGenics Rockville manufacturing site

July 4, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BOLD, CAMP, MGNX, and AKBA Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$0.98 -0.01 (-0.54%)

As of 01:18 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Boundless Bio NASDAQ:BOLD

$2.86 -0.03 (-1.04%)

As of 01:13 PM Eastern

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

CAMP4 Therapeutics NASDAQ:CAMP

$4.08 +0.28 (+7.37%)

As of 01:18 PM Eastern

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location. The company also offers telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things marketplace, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from remote and mobile assets. In addition, it offers professional services, including project management, engineering services, and installation services. The company sells its products and services to customers in the automotive, telecommunications, industrial equipment, transportation and logistics, government and municipalities, insurance, original equipment manufacturers, and leasing companies. It markets through direct sales organization, channel partner program, original equipment manufacturers, and independent sales representatives and distributors, as well as its websites and digital platform. The company was incorporated in 1981 and is headquartered in Irvine, California.

MacroGenics NASDAQ:MGNX

$4.22 -0.10 (-2.31%)

As of 01:19 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BOLD, CAMP, MGNX, and AKBA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BOLD, CAMP, MGNX, and AKBA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BOLD, CAMP, MGNX, and AKBA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BOLD, CAMP, MGNX, and AKBA Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Boundless Bio NASDAQ:BOLD

CAMP4 Therapeutics NASDAQ:CAMP

MacroGenics NASDAQ:MGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BOLD, CAMP, MGNX, and AKBA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BOLD, CAMP, MGNX, and AKBA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BOLD, CAMP, MGNX, and AKBA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BOLD, CAMP, MGNX, and AKBA Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Boundless Bio NASDAQ:BOLD

CAMP4 Therapeutics NASDAQ:CAMP

MacroGenics NASDAQ:MGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools